Vanguard Group Inc Spruce Biosciences, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Spruce Biosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 843,844 shares of SPRB stock, worth $329,099. This represents 0.0% of its overall portfolio holdings.

Number of Shares

843,844

Previous 863,375 2.26%

Holding current value

$329,099

Previous $448,000 11.61%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$0.42 - $0.59 $8,203 - $11,523	-19,531 Reduced 2.26%	843,844 $396,000
Q1 2024 May 10, 2024	BUY	$0.7 - $5.49 $28,689 - $225,007	40,985 Added 4.98%	863,375 $682,000
Q4 2023 Feb 14, 2024	BUY	$1.04 - $2.93 $513,885 - $1.45 Million	494,121 Added 150.52%	822,390 $2.41 Million
Q3 2023 Nov 14, 2023	BUY	$2.04 - $2.54 $135,282 - $168,440	66,315 Added 25.32%	328,269 $741,000
Q2 2023 Aug 14, 2023	BUY	$1.92 - $2.6 $29,521 - $39,977	15,376 Added 6.24%	261,954 $563,000
Q1 2023 May 15, 2023	BUY	$1.15 - $3.17 $139,684 - $385,044	121,465 Added 97.08%	246,578 $544,000
Q4 2022 Feb 10, 2023	BUY	$0.99 - $1.43 $132 - $191	134 Added 0.11%	125,113 $137,000
Q3 2022 Nov 14, 2022	BUY	$1.18 - $2.19 $10,526 - $19,536	8,921 Added 7.69%	124,979 $171,000
Q2 2022 Aug 12, 2022	SELL	$1.28 - $2.23 $48,227 - $84,021	-37,678 Reduced 24.51%	116,058 $202,000
Q1 2022 May 13, 2022	SELL	$1.85 - $4.59 $404,023 - $1 Million	-218,391 Reduced 58.69%	153,736 $309,000
Q4 2021 Feb 14, 2022	BUY	$2.33 - $5.74 $2,975 - $7,329	1,277 Added 0.34%	372,127 $1.66 Million
Q3 2021 Nov 12, 2021	BUY	$6.01 - $11.26 $7,993 - $14,975	1,330 Added 0.36%	370,850 $2.23 Million
Q2 2021 Aug 13, 2021	BUY	$10.12 - $17.46 $3.74 Million - $6.45 Million	369,520 New	369,520 $4.14 Million

Others Institutions Holding SPRB

# of Institutions

Shares Held

15.4M

Call Options Held

16.7K

Put Options Held

1.1K

View Full List

About SPRUCE BIOSCIENCES, INC.

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $9.19M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

More about SPRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Spruce Biosciences, Inc. Transaction History